EP0735856A1 - Konzentriertes mundspüllmittel zur effiziente abgabe von antimikrobielle mittel - Google Patents
Konzentriertes mundspüllmittel zur effiziente abgabe von antimikrobielle mittelInfo
- Publication number
- EP0735856A1 EP0735856A1 EP95906064A EP95906064A EP0735856A1 EP 0735856 A1 EP0735856 A1 EP 0735856A1 EP 95906064 A EP95906064 A EP 95906064A EP 95906064 A EP95906064 A EP 95906064A EP 0735856 A1 EP0735856 A1 EP 0735856A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- water
- antimicrobial
- composition according
- oral composition
- chlorophenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
Definitions
- the present invention relates to a concentrated mouthrinse and methods of use and methods of making the same, wherein there is an efficient delivery of an ⁇ timicrobials to the oral cavity thereby reducing oral bacteria, mouth malodor and further promoting oral health.
- Plaque is an organic rrtixture of living bacteria found in the mouth.
- the bacteria found in plaque can secrete acids, enzymes and microtoxins which can cause caries, oral malodor and periodontal diseases such as gingivitis.
- the compositions of the present invention possess a unique ability to form a concentrated and aesthetically pleasing mouthrinse.
- This invention provides a system by which, upon dilution, relatively low concentrations of germ-killing antimicrobials can be efficiently delivered to the oral cavity. In combination with the delivery of the antimicrobial, it has also been discovered this mechanism efficiently delivers a flavoring agent. This discovery therefore provides, without non-cationic surfactants, excellent taste and breath refreshment, and also efficient delivery of antimicrobial agents providing effective germ -tilling activity, thereby promoting oral health.
- the present invention relates to compositions comprising certain solvents, cationic antimicrobials and noncationic antimicrobials solubilized into a concentrated solution which is aesthetically pleasing.
- This mouthrinse is diluted with water to provide a safe and effective means for reducing bacteria found in the oral cavity and further provides a signal of efficacy to users.
- the antimicrobials and flavoring agents of the present invention are delivered more efficiently while employing similar concentrations.
- a further object of the present invention is to provide mouthrinse compo ⁇ sitions which deliver improved antiplaque benefit.
- Still a further object of the present invention is to provide a safe and effective means of preparing a mouthrinse from the concentrated solution.
- compositions of non-carbonated, concen ⁇ trated, oil-in-water emulsions suitable for use as oral mouthrinses comprising: (a) a safe and effective amount of a cationic antimicrobial agent;
- safety and effective amount means an amount sufficient t reduce oral bacteria and or enhance such reduction while providing no advers effects to the hard and soft tissues of the oral cavity.
- substantially free of anionic surfactant means less tha 0.05%, preferably less than 0.01% and most preferably less than 0.001% of an anionic surfactant.
- substantially free of non-ionic surfactant means an amount which will not substantially impair the activity of the cationic surfactant. Generally, this means the composition must contain less then about 0.5%, preferably less than 0.3% and most preferably less than 0.2% of the nonionic surfactant.
- compositions of this invention employ a cationic antimicrobial agent, a water-insoluble noncationic antimicrobial, a solvent or a mixture of solvents, a flavoring agent or mixture of flavoring agents and water.
- the concentrated mouthrinse is preferably clear.
- “clear” as used herein does not mean colorless, but means substantially lacking the presence of particles of sufficient size to scatter visible light as detected visually.
- the concentrated mouthrinse is mixed with a desired amount of water. This mixing allows for phase separation immediately prior to use.
- phase separation provides an efficient delivery of a sufficient level of antimicrobial agents, while allowing for optimal taste and aesthetics.
- the amount of water added to the concentrated mouthrinse mixture must be high enough to result in the necessary phase change as described below. This phase change is conveniently observed by the user during dilution and provides a visual signal alerting the consumer the composition is ready for use.
- the flavoring oils which are highly water-insoluble become uniformly dispersed within the water phase of the ready-to-use mouthrinse.
- the water-insoluble, noncationic antimicrobial of the present invention combining with the flavor oils, is likewise dispersed throughout this phase.
- the cationic antimicrobials of the present invention due to the inherent properties of both a hydrophobic and hydrophylic moiety, reside primarily at the oil-water interface.
- the hydrophobic moities of the cationic antimicrobial reside within the dispersed oily phase of the bi-phasic mixture whereas the charged, hydrophilic moities of the cationic antimicrobial position themselves around the surface (or oil- water interface) of the oily droplets, forming countless micellar particles. It is the formation of this biphasic mixture and, in particular, the positioning of the cationic antimicrobial at the oil-in-water interface which contributes to the efficient antimicrobial delivery of the present invention.
- the cationic antimicrobial In addition to its antimicrobial activity, the cationic antimicrobial also acts as a magnetic towing device, delivering its micellar contents, which include the water insoluble, noncationic antimicrobial(s), to the oppositely charged surfaces of the oral mucosa. This results in a more efficient delivery of the water insoluble, noncationic antimicrobial as well.
- the water-insoluble, noncationic antimicrobial is not structured so as to ensure primary residence at the oil-water interface, h still enjoys the benefit.
- the pH of the present concentrated compositions range from about 5.0 to about 8.0 with the preferred pH being from about 6.5 to about 7.0 with the most preferred pH being about 6.9.
- the essential, as well as optional components of the compositions of the present invention are described below.
- the cationic antimicrobials used in the compositions of the present invention may be selected from the group consisting of quaternary ammonium compounds and substituted guanidines such as chlorhexidine and the corresponding compound alexidine. Mixtures of these cationic antimicrobials may also be used in the present invention.
- Antimicrobial quaternary ammonium compounds include those in which one or two of the substitutes on the quaternary nitrogen has a carbon chain length (typically alkyl group) from about 8 to about 20, typically from about 10 to about 18 carbon atoms while the remaining substitutes (typically alkyl or benzyl group) have a lower number of carbon atoms, such as from about 1 to about 7 carbon atoms, typically methyl or ethyl groups.
- pyridiniu compounds are the preferred quaternary ammonium compounds, the most preferre being cetylpyridinium chloride or tetradecyipyridinium chloride.
- Quaternar ammonium antimicrobial agents are included in the present invention at levels o about 0.05% to about 10.0-%, preferably from about 0.2% to 3.0%, more preferabl from about 0.5% to about 3.0% and most preferably from about 0.5% to abou 2.0%.
- the substituted guanidines are also suitable for use in this invention.
- Bis biguanide compounds which are preferred for use in the present invention, are thos having the generic formula:
- the water soluble salts of the above compounds are especially preferred for use herein. Suitable water soluble salts include the chloride, the fluoride, and especially the acetate salt.
- the preferred substituted guanidine is chlorhexidine-[l,6-di(-N ⁇ 5>-pchlorophenyl-N-digu ⁇ do)-hexane].
- the substituted guanidine antimicrobials are generally used in the present compositions at a level o from about 0.05% to about 3.0%, preferably from about 0.5% to about 3.0% and most preferably from about 0.5% to about 2.0%.
- Water-insoluble, Noncationic Antimicrobials The second essential component is a water-insoluble, noncatio antimicrobial. Given below are examples of water insoluble, noncatio antimicrobial agents useful to the present invention.
- Phenolic Compounds including phenol and its homologs, mono- and pol alkyl and aromatic halophenols, resorcinol and its derivatives, bisphenolic compoun and halogenated salicylanilides). Phenol and its Homologs Phenol 5-Methyl-2-(l-methy1ethyl) - phenol (Thymol)
- the unique combination of both the cationic and water-insoluble, noncationic antimicrobials delivered in the oil- in-water emulsion of the present invention provides improved antiplaque benefits.
- the water-insoluble noncationic compounds provide an access to bacterial colonies located within plaque matrices not readily available to cationic antimicrobials.
- the novel combination of these two classes of antimicrobials thus, results in a potent antiplaque composition delivering effectiv antiplaque activity regardless of the degree of existing plaque build-up.
- the water-insoluble, noncationic antimicrobial is present in the ora composition prepared using the claimed method in an effective antiplaque amount, typically about 0.01-5% by weight, preferably about 0.03-1%.
- the antimicrobial agent is substantially water-insoluble, meaning that its solubility is less than about 1% by weight in water at 25°C and may be even less than about 0.1%. If an ionizable group is present solubility is determined at a pH at which ionization does not occur.
- solvent or solvent system such as those described in U.S. Patent 5.141.961. August 25, 1992 to Coapman, herein incorporated by reference.
- the solvent(s), which constitute the bulk of the present composition act as a carrier for the flavoring oils.
- the solvent or solvent system solubilizes the flavoring oils in the concentrate and aids in dispersing, upon dilution with added water, all oil soluble components of the concentrated formulation thereby forming a uniformly dispersed mixture.
- the solvents most preferred for use in the present invention are: polyethylene glycols, propylene glycol, butylene glycol and hexylene glycol or mixtures thereof. Propylene glycol being the most preferred.
- Propylene glycol is well known in the art and available from any of a number of suppliers. Propylene glycol is miscibie in all proportions with water and also has the ability to dissolve the flavoring agent(s) of the present invention. Propylene glycol suitable for use in the present invention is obtainable from any number of sources such as Dow Chemical. Polyethylene glycols are also well known in the art and lower molecular weight species possess characteristics similar to propylene glycol. Polyethylene glycols suitable for use in the present invention are the polyethylene glycols having an average molecular weight of less than or equal to 600, such as PEG 300 "Carbowax" supplied by Union Carbide. Solvents comprise from about 30% to about 90%, preferably from about 35% to about 80% and most preferably from about 45% to about 80% of the concentrated form of the mouthrinse.
- Water Water is present in the concentrated composition of the present invention. Water comprises from about 10% to about 40%, preferably from about 10% to about 30% and most preferably from about 10% to about 25% of the oral compositions described herein. These amounts of water include the free water which is added, plus that amount which is introduced with other materials such as with sorbitol. Th water, used in the present invention should preferably be deionized, distilled, free o organic impurities and bacteria and substantially free of metal ions.
- flavoring agent Another essential ingredient of the present invention is a flavoring agent or mixture of compatible flavoring agents.
- suitable flavoring agents include: anise, cassia, clove, dihydroanethole estragole, menthol, peppermint, oxanone, phenyl ethyl alcohol, sweet birch, thymol eugenol, eucalyptol, wintergreen, spearmint, cinnamic aldehyde, menthone, alpha-ionone, ethyl vanillin, limonene, isoamylacetate, benzaldehyde, ethylbutyrat and many others.
- the flavoring agents compris from about 0.2% to about 9.0%, preferably from about 0.6% to about 4.0% and most preferably from about 2.0% to about 4.0% of the herein described composition.
- An optional ingredient useful in the present invention is a humectant or mixture of compatible humectants.
- Humectants are well known in the art.
- suitable humectants include the poryhydric alcohols such as xylitol- glycerin and sorbitol as well as other polyhydroxy alcohols and mixtures of these humectants.
- Humectants provide from 0% to about
- humectants includes glycerin and sorbitol in a ratio of about 10: 1 to about 1 :4, and most preferably from about 3: 1 to about 1 :2.
- Ethyl alcohol provides several functions when combined in the compositions of the present invention. Its inclusion can be, but is not limited to use as an additional antimicrobial or as an astringent. Ethyl alcohol can be incorporated in the present invention at a level of less than about 40%, preferably less than about 10% and most preferably in concentrations of less than 2%.
- Still another optional component of the present invention is a cooling agent such as those described in U.S. Patent 4.136.163. January 23, 1979, to Watson et al, U.S. Patent 4.230.668. October 28, 1980 to Rowsell et al. and U.S. Patent 4.032.661. to Rowsell et al. all herein incorporated by reference.
- a cooling agent such as those described in U.S. Patent 4.136.163. January 23, 1979, to Watson et al, U.S. Patent 4.230.668. October 28, 1980 to Rowsell et al. and U.S. Patent 4.032.661. to Rowsell et al. all herein incorporated by reference.
- One particularly preferred cooling agent is N-ethyl-p-menthane-3-carboxamide (WS-3 supplied by Sterling Organics), taught by the above incorporated U.S. Patent 4.136.163.
- the present invention to be effectively used as an antimicrobial mouthrinse should be prepared by the user just prior to use by adding an aqueous solution, preferably water to the concentrated oil-in-water emulsion or by adding the con ⁇ centrated oil-in-water emulsion to water.
- an aqueous solution preferably water to the concentrated oil-in-water emulsion or by adding the con ⁇ centrated oil-in-water emulsion to water.
- the oil-in-water emulsion breaks, leaving the diluted composition cloudy (or opaque). This generally occurs with the addition to the emulsion of greater than 5% v/V, preferably from about 10% and most preferably from about 20% of an aqueous solution. Therefore, after dilution, the resulting composition is not completely transparent. This transformation can be visually observed, or can be readily measured using a spectrophotometer.
- any appreciable difference in the absorbance of light as between the undiluted concentrate and the diluted concentrate signifies the interaction and diffusion of light necessary to the invention, establishing the range of "cloudiness.”
- No additional agitation or mixing energy is required to cause rapid dispersion, forming a uniformly dispersed mixture of the compositions antimicrobials), flavoring oil(s) and other ingredients.
- the dilution of the mouthrinse concentrate requires mixing the concentrate with water in a range of ratios from about 1:1 to about 1:100, preferably from about 1:2 to about 1:50, more preferably from about 1:5 to about 1:50 and most preferably from about 1:20 to about 1:50.
- COMPOSITION USE in its method aspect involves rinsing the oral cavity with a safe and effective amount of a mouthrinse prepared by the user by diluting the herein described concentrate with a suitable amount of water.
- a safe and effective amount of a mouthrinse prepared by the user by diluting the herein described concentrate with a suitable amount of water.
- an amount of at least about 0.01 grams of the antimicrobial becomes available by diluting the concentrate as described above and is effective in eliminating or reducing the bacterial flora residing within the oral cavity.
- a concentrated mouthrinse of the present invention is prepared by combini the following ingredients as described below. Also given is the dilution factor diluting the concentrated composition.
- the diluted composition will become cloudy signaling the user the mouthrin is ready for use.
- the user then rinses the oral cavity with approximately 20 ml of th diluted composition and expels the mouthrinse. This use reduces or eliminates t bacteria found in the oral cavity, preventing gingivitis and oral calamity.
- Examples H & DI are combinations are manufactured in a manne substantially similar to Example I.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17157693A | 1993-12-22 | 1993-12-22 | |
US171576 | 1993-12-22 | ||
PCT/US1994/014757 WO1995017159A1 (en) | 1993-12-22 | 1994-12-21 | Concentrated mouthrinse for efficient delivery of antimicrobials |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0735856A1 true EP0735856A1 (de) | 1996-10-09 |
Family
ID=22624283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95906064A Ceased EP0735856A1 (de) | 1993-12-22 | 1994-12-21 | Konzentriertes mundspüllmittel zur effiziente abgabe von antimikrobielle mittel |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0735856A1 (de) |
JP (1) | JPH09510186A (de) |
CN (1) | CN1137750A (de) |
PE (1) | PE44595A1 (de) |
WO (1) | WO1995017159A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440395B1 (en) | 1992-06-22 | 2002-08-27 | Barry M. Libin | Antiplaque mouth rinse |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
JPH10501265A (ja) * | 1994-06-10 | 1998-02-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | マウスリンス組成物 |
EP0764015B1 (de) * | 1994-06-10 | 2000-04-19 | The Procter & Gamble Company | Mundspülungsmittel |
US6864269B2 (en) | 1996-04-12 | 2005-03-08 | University Of Arkansas | Concentrated, non-foaming solution of quarternary ammonium compounds and methods of use |
US5891422A (en) * | 1996-10-10 | 1999-04-06 | Warner-Lambert Company | Antimicrobial composition containing a C3 -C6 alcohol |
US6436369B2 (en) * | 1998-12-17 | 2002-08-20 | Wm. Wrigley Jr. Company | Anti-plaque emulsions and products containing same |
US8283135B2 (en) * | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
US9241885B2 (en) * | 2004-01-29 | 2016-01-26 | The Procter & Gamble Company | Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials |
US8517728B2 (en) | 2007-01-24 | 2013-08-27 | Colgate-Palmolive Company | Oral care implement having fluid delivery system |
TWI392514B (zh) | 2010-01-29 | 2013-04-11 | Colgate Palmolive Co | 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑 |
JP5804307B2 (ja) * | 2010-03-03 | 2015-11-04 | サンスター株式会社 | 口腔用組成物 |
WO2012015420A1 (en) * | 2010-07-30 | 2012-02-02 | Colgate-Palmolive Company | Mouthwash formulations for use with toothbrush delivery device |
AU2011361752B2 (en) | 2011-03-09 | 2015-01-22 | Colgate-Palmolive Company | Interdental cleaning device |
CN103906500B (zh) * | 2011-11-09 | 2017-08-08 | 高露洁-棕榄公司 | 无酒精漱口水 |
CN103190962A (zh) * | 2012-01-04 | 2013-07-10 | 江苏雪豹日化有限公司 | 一种口腔海绵清洁棒的制造方法 |
US20130344120A1 (en) * | 2012-06-21 | 2013-12-26 | Douglas Craig Scott | Mouth Rinse Emulsions |
US9554641B2 (en) | 2012-10-26 | 2017-01-31 | Colgate-Palmolive Company | Oral care implement |
EP2934463B1 (de) * | 2012-12-20 | 2018-02-14 | Colgate-Palmolive Company | Mundpflegezusammensetzung mit ionischen flüssigkeiten |
WO2019174277A1 (en) * | 2018-03-13 | 2019-09-19 | The Hong Kong Polytechnic University | Phosphoethanolamine transferase inhibitors |
EP4164586A1 (de) | 2020-06-15 | 2023-04-19 | Unilever IP Holdings B.V. | Antimikrobielle zusammensetzung zum tacking von schlechtem geruch |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1365030A (en) * | 1972-11-30 | 1974-08-29 | Merck & Co Inc | Oral compositions |
US4205061A (en) * | 1978-07-14 | 1980-05-27 | Johnson & Johnson | Oral antimicrobial compositions |
DE3345781A1 (de) * | 1983-12-17 | 1985-06-27 | Henkel KGaA, 4000 Düsseldorf | Mund- und zahnpflegemittel |
ZA872857B (en) * | 1986-05-02 | 1987-11-25 | Warner Lambert Co | Composition and method to inhibit the growth of organisms by the use of bis-biguanido hexanes and essential oil mixture combinations |
US4666517A (en) * | 1986-06-04 | 1987-05-19 | Colgate-Palmolive Co. | Antiplaque oral composition |
US4992276A (en) * | 1988-12-14 | 1991-02-12 | Warner-Lambert Company | Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same |
US5236699A (en) * | 1992-06-22 | 1993-08-17 | Libin Barry M | Antiplaque mouth rinse |
US5405604A (en) * | 1992-10-16 | 1995-04-11 | The Procter & Gamble Company | Concentrated mouthrinse for efficient delivery of antimicrobials |
-
1994
- 1994-12-21 EP EP95906064A patent/EP0735856A1/de not_active Ceased
- 1994-12-21 WO PCT/US1994/014757 patent/WO1995017159A1/en not_active Application Discontinuation
- 1994-12-21 CN CN 94194545 patent/CN1137750A/zh active Pending
- 1994-12-21 PE PE25760194A patent/PE44595A1/es not_active Application Discontinuation
- 1994-12-21 JP JP7517586A patent/JPH09510186A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9517159A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1137750A (zh) | 1996-12-11 |
PE44595A1 (es) | 1996-01-10 |
WO1995017159A1 (en) | 1995-06-29 |
JPH09510186A (ja) | 1997-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5405604A (en) | Concentrated mouthrinse for efficient delivery of antimicrobials | |
EP0735856A1 (de) | Konzentriertes mundspüllmittel zur effiziente abgabe von antimikrobielle mittel | |
AU682489B2 (en) | Reduced alcohol mouthwash antiseptic and antiseptic preparations | |
US3947570A (en) | Oral product | |
US5681549A (en) | Mouthrinse compositions | |
DE69205527T2 (de) | Aminosilikon und eine lipophile Verbindung enthaltende orale Zusammensetzungen. | |
US5256401A (en) | Antibacterial antiplaque mouthwash composition | |
US6861048B2 (en) | Dentifrice compositions having reduced abrasivity | |
CA2200977C (en) | Aqueous oral compositions | |
LU84833A1 (fr) | Produit de nettoyage pour les soins des dents et de la bouche contenant un tensio-actif non ionique poly(hydroxypropyl ether) | |
CN110114050A (zh) | 口腔护理产品及其使用和制备方法 | |
DE69415515T2 (de) | Orale präparate zur behandlung von plaque und gingivitis, die einen nicht-kationischen antibakteriellen wirkstoff und ein bikarbonatsalz enthalten | |
WO1992020319A1 (fr) | Composition pour l'hygiene bucco-dentaire et son procede d'utilisation | |
RU2358710C2 (ru) | Композиции для полоскания полости рта, содержащие соли алкиловых эфиров n-ациларгинина | |
WO1995034276A1 (en) | Mouthrinse compositions | |
JPS6351341A (ja) | アズレン含有液剤 | |
JP2627709B2 (ja) | 口腔用組成物 | |
JP2007055976A (ja) | 練歯磨組成物 | |
KR20120112538A (ko) | 유화형 액체 구강용 조성물 및 그 제조 방법 | |
WO2014078198A1 (en) | Oral care compositions | |
JPH0672833A (ja) | 歯磨剤の製造方法 | |
JPH10324619A (ja) | 口腔用組成物 | |
JP5720352B2 (ja) | 液体口腔用組成物 | |
JPH0748237A (ja) | 口腔用組成物 | |
CA2358832A1 (en) | Method of reducing dentrifice compositions abrasivity by incorporation of zinc citrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960612 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19970807 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19990417 |